|
Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial. |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Clarity Pharmaceuticals; EUSA Pharma; Roche; Ymabs Therapeutics Inc |
Speakers' Bureau - Ymabs Therapeutics Inc |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
Consulting or Advisory Role - Bayer (Inst) |
|
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Pfizer (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Bayer (Inst); Lilly (Inst); Salarius Pharmaceuticals; Thermo Fisher Scientific |
(OPTIONAL) Uncompensated Relationships - American Society of Pediatric Hematology/Oncology; Children's Oncology Group Foundation; The Pablove Foundation |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer |
Travel, Accommodations, Expenses - Bayer |
|
|
Honoraria - Bayer; Y-mAbs Therapeutics |
Consulting or Advisory Role - Bayer; Y-mAbs Therapeutics |
Travel, Accommodations, Expenses - Bayer |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Roche |
Travel, Accommodations, Expenses - Bayer; Roche |
|
|
|
Consulting or Advisory Role - Debbio; EUSA Pharma; Loxo/Bayer; Merck |
|
Catherine Michelle Albert |
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
Consulting or Advisory Role - Bayer; Cellectis; Lilly; Loxo; Novartis |
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst) |